The Markey Cancer Center (MCC) Protocol Review and Monitoring System (PRMS) provides thorough review of clinical trials for scientific validity, feasibility and prioritization within the clinical trials portfolio and monitoring of scientific progress. The PRMS must approve all interventional cancer research prior to study initiation and has the authority to recommend closure of trials for lack of scientific progress or patient accrual. The PRMS provides a framework which aims to balance appropriate resource utilization while maximizing the opportunities for current and future patients with cancer in this region to participate in clinical trials, including the underserved area of Appalachian Kentucky. The development of novel MCC investigator-initiated clinical trials and participation in high-priority national trials provide a robust portfolio of therapeutic research studies available to MCC patients.
The patients of the MCC represent a diverse population with the highest incidence rates of lung and colorectal cancers in the United States, high rates of poverty and increased rates of important risk behaviors (i.e., smoking and low screening rates for some cancers). These challenges require a well-developed PRMS to facilitate effective clinical and translational trials to overcome the health disparities of this region and lead to improvement in cancer survival.
|Shi, Jian; Wang, Yifan; Zeng, Lei et al. (2014) Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 25:210-25|
|Tuna, Halide; Avdiushko, Rita G; Sindhava, Vishal J et al. (2014) Regulation of the mucosal phenotype in dendritic cells by PPAR?: role of tissue microenvironment. J Leukoc Biol 95:471-85|
|Huang, Yan; Hu, Yin; Liu, Jinze (2014) Piecing the puzzle together: a revisit to transcript reconstruction problem in RNA-seq. BMC Bioinformatics 15 Suppl 9:S3|
|Chen, Li; Voronovich, Zoya; Clark, Kenneth et al. (2014) Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 16:1478-83|
|Barone, Eugenio; Di Domenico, Fabio; Butterfield, D Allan (2014) Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol 88:605-16|
|Förster, Sarah; Welleford, Andrew S; Triplett, Judy C et al. (2014) Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochim Biophys Acta 1842:1333-9|
|Gilbert, Misty R; Liu, Yinxing; Neltner, Janna et al. (2014) Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol 127:221-33|
|Farr, Susan A; Ripley, Jessica L; Sultana, Rukhsana et al. (2014) Antisense oligonucleotide against GSK-3? in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 67:387-95|
|Cenini, Giovanna; Fiorini, Ada; Sultana, Rukhsana et al. (2014) An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radic Biol Med 76:89-95|
|Liu, Yinxing; Gilbert, Misty R; Kyprianou, Natasha et al. (2014) The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathol 128:723-32|
Showing the most recent 10 out of 17 publications